[ NATIONAL · PE ]
A directorate-general for medicines, supplies and drugs sitting inside the health ministry rather than beside it.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
LATIN AMERICA
SPEQ has not decoded the principal instrument for Peru to the standard this module requires, and states that rather than naming one. What is decoded is institutional and load-bearing: the medicines authority is a directorate-general — the Dirección General de Medicamentos, Insumos y Drogas — sitting inside the health ministry rather than standing beside it as an independent agency. Requirements therefore arrive as ministerial instruments and are administered within the ministry’s structure.
Through sanitary registration of the product and good-manufacturing-practices certification of the site that makes it, including sites outside the country. The directorate inspects and certifies, and where it does not inspect a foreign site directly it may rely on certification issued in the country of origin — which moves the practical constraint upstream, onto which authority issued the certificate a company already holds.
WHAT TRANSFERS
This is where the honest answer matters most. SPEQ has not decoded ICH or PIC/S participation for Peru. That is a statement about this catalog rather than a finding about the regulator, and it should be read as "confirm the current position with the authority" and not as "Peru participates in nothing". Until it is confirmed, treat evidence from those systems as supporting context to be explained rather than as currency that carries on its own.
The institutional position shapes how instruments are issued and how decisions are escalated. An organisation used to dealing with an independent agency should expect ministerial process rather than agency process.
Where the directorate relies on a certificate from the country of origin, the identity and standing of the issuing authority becomes the substantive question. That makes sequencing — which market you certify in first — a decision with downstream consequences.
Sanitary registration addresses the product; certification addresses the site. Both are needed, and effort is routinely concentrated on the first.
Because SPEQ has not decoded the harmonizer position here, any plan that depends on evidence transferring should be checked directly with the authority before dates are committed.
The Dirección General de Medicamentos, Insumos y Drogas, a directorate-general within the health ministry rather than an independent agency standing beside it.
It can form part of the picture. Where the directorate does not inspect a foreign site directly it may rely on certification issued in the country of origin, which makes the issuing authority’s standing the substantive question.
SPEQ has not decoded a position on either for Peru, and does not assert one. That is a gap in this catalog rather than a finding about the authority; confirm the current position with the regulator before planning around evidence transfer.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about Peru: requirements still arrive through the authorities below, and the edition in force is theirs to state.
SPEQ records no harmonizer participation for Peru. Requirements here are set by the authorities above rather than arriving through a harmonized guide, so evidence prepared for another market does not transfer on that basis.